Livzon Pharmaceutical Group Inc
SZSE:000513
Gross Margin
Livzon Pharmaceutical Group Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CN |
|
Livzon Pharmaceutical Group Inc
SZSE:000513
|
32.8B CNY |
64%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
783.4B USD |
81%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
389.2B USD |
69%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.2T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
233.7B CHF |
73%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
174.1B GBP |
82%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
223.1B USD |
81%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
198.6B CHF |
75%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.8B USD |
74%
|
Livzon Pharmaceutical Group Inc
Glance View
Nestled within the bustling pharmaceutical landscape of China, Livzon Pharmaceutical Group Inc. has meticulously carved its path since its inception in 1985, blossoming into a formidable player in the industry. Based in Zhuhai, Guangdong Province, the company has steadily built a diversified portfolio across the pharmaceutical spectrum, focusing on both traditional Chinese medicine and modern biopharmaceutical products. Livzon leverages its robust research and development (R&D) capabilities to produce an extensive range of medications, catering primarily to major therapeutic areas such as cardiovascular, gastrointestinal, anti-infective, and oncology segments. With rigorous standards driving their production lines, they ensure premium quality, which has bolstered their reputation and allowed them to secure numerous patents and proprietary products. Livzon's revenue engine is fueled by its strategic blend of manufacturing prowess and a well-tuned distribution network. The company operates a comprehensive production chain, from raw material sourcing and pharmaceuticals manufacturing to extensive distribution channels stretching across domestic and global markets. It sustains strong collaborations with hospitals, medical institutions, and pharmacies, which facilitate widespread accessibility and market penetration. Additionally, Livzon invests heavily in innovation, aligning with global health demands through strategic partnerships and joint ventures, further pushing the boundaries of research. By balancing traditional medicinal wisdom with cutting-edge technologies, Livzon positions itself as an agile competitor in the ever-evolving pharmaceutical arena, continuously driving value creation and securing its foothold in the global marketplace.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Livzon Pharmaceutical Group Inc's most recent financial statements, the company has Gross Margin of 64.3%.
You don't have any saved screeners yet